SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Motohiro Shimizu, Satoshi Hiramine, Fujiko Mitsumoto, Kazuya Ura, Kazuhiro Toyoda, Masayuki Murata, Jun Hayashi, A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy, Journal of Infection and Chemotherapy, 2014, 20, 9, 577

    CrossRef

  2. 2
    Warren N. Schmidt, David R. Nelson, Jean–Michel Pawlotsky, Kenneth E. Sherman, David L. Thomas, Raymond T. Chung, Direct-Acting Antiviral Agents and the Path to Interferon Independence, Clinical Gastroenterology and Hepatology, 2014, 12, 5, 728

    CrossRef

  3. 3
    Maria Buti, Rafael Esteban, Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’, Expert Review of Gastroenterology & Hepatology, 2014, 1

    CrossRef

  4. 4
    Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, Emanuela Zappulo, Giuseppe Castaldo, Guglielmo Borgia, MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection, Expert Opinion on Investigational Drugs, 2014, 23, 5, 719

    CrossRef

  5. 5
    Jianjian Fu, Jing Wei, Molecular dynamics study on drug resistance mechanism of HCV NS3/4A protease inhibitor: BI201335, Molecular Simulation, 2014, 1

    CrossRef

  6. 6
    Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, Vincent Launay-Vacher, New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment, Drugs, 2014, 74, 12, 1307

    CrossRef

  7. 7
    Reneé C. Ireton, Michael Gale, Pushing to a cure by harnessing innate immunity against hepatitis C virus, Antiviral Research, 2014, 108, 156

    CrossRef

  8. 8
    Victoria Belousova, Ahmed A. Abd-Rabou, Shaker A. Mousa, Recent advances and future directions in the management of hepatitis C infections, Pharmacology & Therapeutics, 2014,

    CrossRef

  9. 9
    Tara L Kieffer, Shelley George, Resistance to hepatitis C virus protease inhibitors, Current Opinion in Virology, 2014, 8, 16

    CrossRef

  10. 10
    Stella De Nicola, Alessio Aghemo, Second wave anti-HCV protease inhibitors: too little too late?, Liver International, 2014, 34, 7
  11. 11
    Andrea De Luca, Claudia Bianco, Barbara Rossetti, Treatment of HCV infection with the novel NS3/4A protease inhibitors, Current Opinion in Pharmacology, 2014, 18, 9

    CrossRef

  12. 12
    AiPing Duan, LiMin Ning, Chao Li, YaFei Hou, NaNa Yang, LiZhou Sun, GenXi Li, A novel strategy to inhibit the reproduction and translation of hepatitis C virus, Science China Life Sciences, 2013, 56, 4, 293

    CrossRef

  13. 13
    Sonal Kumar, Ira Jacobson, All Oral HCV Therapies of the Future, Current Hepatitis Reports, 2013, 12, 4, 214

    CrossRef

  14. 14
    Troels K H Scheel, Charles M Rice, Understanding the hepatitis C virus life cycle paves the way for highly effective therapies, Nature Medicine, 2013, 19, 7, 837

    CrossRef

  15. 15
    Hanadi Qashqari, Amany Al-Mars, Adeel Chaudhary, Adel Abuzenadah, Ghazi Damanhouri, Mohammed Alqahtani, Maged Mahmoud, Maysaa El Sayed Zaki, Kaneez Fatima, Ishtiaq Qadri, Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance, Infection, Genetics and Evolution, 2013, 19, 113

    CrossRef